[{"id":"f34327ea-f002-4122-8c11-9595b9888d7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05578092","created_at":"2022-10-13T17:58:11.601Z","updated_at":"2025-02-25T13:49:34.674Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway","source_id_and_acronym":"NCT05578092","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" EGFR • KRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12","tags":["EGFR • KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • MRTX0902"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 12/02/2022","start_date":" 12/02/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-21"}]